THE PURE-PLAY DERMATOLOGY CATEGORY LEADER
We deliver an innovative, science-based portfolio of premium cutting-edge brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology
2021 HIGHLIGHTS
1.
Restylane® Defyne FDA-approved for chin augmentation
2.
New approvals in China including Restylane Lyft Nose, Restylane Defyne, Restylane Lyft Lidocaine Midface
3.
Re-energized Galderma brand identity reflecting both our 40-year heritage of innovation in dermatology and our vision for tomorrow
4.
Positive decision for use in Europe of Alluzience®, the first ready-to-use BoNT-A neuromodulator
5.
Renewed commitment of Cetaphil® to environmental sustainability and social impact through the Clear Skies initiative
6.
Biostimulator Sculptra® label update in the U.S. for immediate use after reconstitution and more convenient administration. Re-launch in Europe with new administration protocol
7.
Launch of Restylane® Eyelight™, a new solution to combat under-eye shadows
8.
Acquisition of the award-winning Alastin Skincare®, dedicated to developing innovative and clinically-tested physician-dispensed skincare products
9.
Exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology
10.
Exclusive licenses for the commercialization of Epsolay® and Twyneo® in the U.S.
11.
Presentation of new nemolizumab data reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis
12.
Celebration of 25 years of unmatched achievement for Restylane®, the original stabilized hyaluronic acid filler
CEO FOREWORD
“Since launching as a stand-alone company in 2019, we have made great progress in realizing our full potential. Today, we operate as a simple, coherent and integrated dermatology company that is unique in our ability to reach the whole spectrum of consumers and healthcare professionals through a truly omni-channel, go-to-market strategy. We have oriented our business around the consumer with dermatology as our common platform.
With our complete dedication to dermatology and over 40 years of scientific innovation in this field, we are uniquely positioned for leadership and growth in this market”.
OUR UNIQUE INTEGRATED DERMATOLOGY STRATEGY
Our unique Integrated Dermatology Strategy is a key differentiator for Galderma by creating greater consumer, patient and healthcare professional engagement, generating better customer insights and delivering continuous innovation.
It is the driving force behind our strong performance, and we believe it will continue to accelerate our financial performance and deliver on our growth ambition in the years to come.
LEARN MORE ON OUR INTEGRATED DERMATOLOGY STRATEGY
POISED FOR GROWTH IN FAST-GROWING DERMATOLOGY MARKETS
Since becoming a stand-alone company, we have shown accelerating performance momentum. Galderma is, first and foremost, a growth story.
2021 has been another pivotal year in Galderma’s growth journey. We have established Galderma as a simple, coherent and integrated dermatology company reaching the whole spectrum of consumers and healthcare professionals through an omni-channel go-to-market strategy. Our business is oriented around the consumer with dermatology as our common platform. This is supported by our portfolio of premium positioned brands and services across three product categories, Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology.
Injectable Aesthetics
In Injectable Aesthetics, Dysport and Restylane are leading brands by market share globally in neuromodulators and fillers, respectively, with premium positioning in their categories supported by clear product differentiation, while Sculptra is the market leader in the rapidly-growing biostimulators category.
Dermo-cosmetics
Our Dermo-cosmetics platform is headlined by Cetaphil, the number 1 doctor-recommended sensitive skincare brand in the U.S. with 75 years of 'white-coat' endorsement. In addition to our portfolio of regional brands, we are expanding into the physician-dispensed skincare segment with the acquisition of Alastin, the number 1 preferred skincare and the fastest growing brand in the U.S. professional skincare market in 2020.
Therapeutic Dermatology
In Therapeutic Dermatology, we are category leaders in prescription treatments for acne with Epiduo (the number 1 prescription topical acne treatment by market share in the U.S.) and for rosacea with Oracea and Soolantra (the number 1 oral and tropical treatments for rosacea by market share respectively). In over-the-counter treatments, Differin is the number 1 brand for acne by market share in the U.S., Benzac is one of the top two brands by market share in multiple markets outside the U.S., and Loceryl is the number 1 nail anti-fungal brand globally by market share.
LEARN MORE ON OUR SYNERGISTIC, SCIENCE-BASED FLAGSHIP BRANDS
DOUBLING DOWN ON SCIENCE
Galderma stands out as one of the few players capable of inventing, developing and bringing to market truly innovative dermatological solutions. Our integrated R&D platform unlocks benefits and synergies across all our product categories.
Galderma’s global team of over 640 R&D professionals has initiated approximately 400 clinical trials across over 20 indications since 2019 and helped us obtain 80 major regulatory approvals since January 2020. Today, we are focused on accelerating development and commercializing our late-stage product candidates to bring new solutions to market faster.
EXPLORE OUR WORLD OF INNOVATION
OUR MANUFACTURING FOOTPRINT IS READY TO SERVE GLOBAL DEMAND
Our four manufacturing plants are strategically located in Canada, Sweden, France and Brazil, serving more than 90 countries with over 280 million units produced annually.
Our site in Uppsala, Sweden, is focused on our injectable aesthetics portfolio. Our Alby-sur-Chéran, France site serves all markets except the U.S. with topicals – both over-the-counter (OTC) and prescription medicine – and supplies brands such as Differin, Aklief and Epiduo. Our largest production site, at Baie-D’Urfé, Canada, is focused on the global supply of Cetaphil, with additional production of OTC and prescription medicine for the U.S. market. The Latin American market is predominantly served by our site in Hortolândia, Brazil.
OUR ACCOMPLISHMENTS
90 Countries
We serve more than 90 countries globally with over 280 million units produced a year.
Over 1,600 colleagues
in manufacturing, commercial quality and supply chain functions work at our four manufacturing plants.
Approximately 75%
of our units sold are produced in-house in four manufacturing facilities.
COVID-19
Despite the challenges of the COVID-19 crisis, we have been able to keep all manufacturing sites operational to date.
Low Injury Rate
We have succeeded in maintaining a low global Recordable Injury Rate (1.2 per million working hours), meaning no severe, irreversible injuries were recorded.
3 of 4
factory sites use 100% renewable electricity from a combination of solar, wind, hydropower, geothermal, biofuel and biomass.
100% renewable electricity by 2024
Our fourth factory is on track to be powered by 100% renewable electricity by 2024.
99% renewable
Currently, more than 99% of renewable electricity is supplied to our four factories, and two are certified Carbon Neutral.
Zero waste-to-landfill
Our four factories achieved zero waste-to-landfill ahead of our initial 2020 plan.
LEARN MORE ABOUT OUR APPROACH TO MANUFACTURING
A DEDICATED TEAM WITH A PROVEN TRACK RECORD FOCUSED ON A BROADER PURPOSE
We seek bold and sophisticated talent with the capacity to innovate, collaborate and execute across teams and geographies to deliver outstanding results, and our teams bring diverse skills, innovation and passion to their work every day. Empowering our employees to make an impact at Galderma and to pursue career growth opportunities is of paramount importance to us.
LEARN MORE ABOUT CAREERS IN GALDERMA
OUR BOLD ENVIRONMENTAL, SOCIAL AND GOVERNANCE RESPONSIBILITY ROADMAP
Environmental, Social and Governance (ESG) is integral to our growth outlook and deeply rooted within all dimensions of our business ambition to become the leading dermatology company in the world. Detailed in the framework above, our ESG journey is focused on four key stakeholders: Employees, Patients & Consumers, Healthcare Professionals & Customers, and Society.
